WilmerHale Represents Placement Agent in $60M Provention Bio Private Placement
WilmerHale represented the sole placement agent in the private placement of 13,318,535 shares of common stock and warrants to purchase up to 13,318,535 shares of common stock of Provention Bio, Inc., a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The private placement priced on July 7, 2022 at $4.38 per share and $0.125 per warrant and closed on July 13, 2022, resulting in gross proceeds to Provention of approximately $60 million, before deducting placement agent fees and offering expenses. The private placement investors included Sessa Capital and Armistice Capital Master Fund Ltd. The WilmerHale team advising the sole placement agent consisted of
Lisa Firenze,
Glenn Pollner,
Katharine Patterson and
Kevin Cheng, with assistance from
Bruce Manheim and
Colleen Superko.
